Research Topics
Species | W D FiggSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failuresXuan Huang
Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
J Hematol Oncol 5:35. 2012....- Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysisSarah M Troutman
Molecular Pharmacology Section, National Cancer Institute, Bethesda, Maryland 20892, USA
Oncologist 17:312-20. 2012..Though several studies have demonstrated an association between certain 8q24 SNPs and clinicopathological features of the disease, review of this topic revealed conflicting results... - Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in miceErin R Gardner
Clinical Pharmacology Program, SAIC Frederick, Inc, NCI Frederick, Frederick, Maryland 21702, USA
J Exp Clin Cancer Res 28:99. 2009..The effect of inhibiting these transporters on tissue exposure to imatinib remains unclear... - Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenibLokesh Jain
Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Exp Clin Cancer Res 29:95. 2010..We hypothesized that these toxicities would correspond to favorable outcome in these drugs, that HT and HFSR would coincide, and that VEGFR2 genotypic variation would be related to toxicity and clinical outcomes... - Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patientsIlaria Pastina
Department of Medical Oncology, Pisa University Hospital, Pisa, Italy
BMC Cancer 10:511. 2010..Functional polymorphisms within the cytochrome P450 1B1 (CYP1B1) gene have been associated with alterations in enzymatic expression and activity and may change sensitivity to the widely used docetaxel regimen... 
Scientific collaboration results in higher citation rates of published articlesWilliam D Figg
Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Pharmacotherapy 26:759-67. 2006..The secondary objective was to analyze the relationship between the number of authors/article and the number of institutions/article for the period of study...- A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastasesWilliam D Figg
Center for Cancer Research, National Cancer Institute, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
J Urol 173:790-6. 2005..The pharmacokinetics of KT and AL were characterized and changes in circulating angiogenic factors were assessed... - A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancerWilliam D Figg
Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Urol 183:2219-26. 2010.... - The Pharm.D. investigator in clinical pharmacology: supply and demandW D Figg
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Clin Pharmacol Ther 84:526-9. 2008..This expanded understanding is important as we start to address the overwhelming mandate and the unfortunate shortage of qualified investigators in the field (both physicians and non-physicians)... - Disclosing a diagnosis of cancer: where and how does it occur?William D Figg
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Clin Oncol 28:3630-5. 2010..We examined how cancer diagnoses were first given to patients and the impact of different aspects of disclosure on patient satisfaction... 
Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy researchWilliam D Figg
National Cancer Institute, Bethesda, Maryland, USA
Pharmacotherapy 28:821-33. 2008..This report also puts forth recommendations for educating future pharmaceutical scientists...- The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancerWilliam D Figg
Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Clin Pharmacol Ther 79:1-8. 2006 - Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancerWilliam D Figg
Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, Cancer Therapy and Evaluation Program, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD 20892, USA
BJU Int 99:1047-55. 2007.... - Prostate cancer - 6th International CongressWilliam D Figg
Molecular Pharmacology Section, Cancer Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
IDrugs 9:675-8. 2006 - A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancerW D Figg
Medicine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 7:1888-93. 2001..Prostate cancer is dependent on the recruitment of new blood vessels to grow and metastasize. Based on those data, we initiated a Phase II trial of thalidomide in patients with metastatic androgen-independent prostate cancer... - Pharmacokinetics of thalidomide in an elderly prostate cancer populationW D Figg
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Building 10, Room 5A01, 9000 Rockville Pike, Bethesda, Maryland 20892, USA
J Pharm Sci 88:121-5. 1999..A dose-proportional increase in thalidomide steady-state concentrations was seen after multiple daily dosing of thalidomide... - Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokineticsWilliam D Figg
Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Cancer Biol Ther 5:840-1. 2006 - Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancerM A Rudek
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Clin Oncol 19:584-92. 2001..042). CONCLUSION: COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy. Phototoxicity was dose-limiting. We recommend the dose of 36 mg/m2/d for phase II trials... - A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interactionE C Kohn
Medicine Branch, National Cancer Institute, and Warren G Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 7:1600-9. 2001..Preclinical and clinical investigation of the combination of the antiangiogenesis/anti-invasion agent carboxyamido-triazole (CAI) administered with the cytotoxic agent paclitaxel (PAX)... - Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancerN A Dawson
Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
J Clin Oncol 15:1470-7. 1997..To assess the efficacy and toxicity of suramin, hydrocortisone, leuprolide, and flutamide in previously untreated metastatic prostate cancer... - Clinical pharmacology of UCN-01: initial observations and comparison to preclinical modelsE A Sausville
DTP Clinical Trials Unit, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
Cancer Chemother Pharmacol 42:S54-9. 1998..Specific binding to human alpha1-acidic glycoprotein has been demonstrated. These findings reinforce the need to consider actual clinical pharmacology data in "real time" with phase I studies... - Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell linesM V Blagosklonny
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bldg 10, 12N226, Bethesda, MD 20892, USA
Int J Oncol 18:697-704. 2001..2 nM) and UCN-01. In PrEC, UCN-01 downregulated cyclin D1 and arrest growth with an IC50 less than 100 nM. We conclude that loss of sensitivity to either UCN-01 or PMA accompanies progression of prostate cancer... - A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar)S Bates
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Cancer 92:1577-90. 2001..The authors conducted a Phase I study of orally administered PSC 833 in combination with vinblastine administered as a 5-day continuous infusion... - Reversal of multidrug resistance: lessons from clinical oncologySusan F Bates
Molecular Therapeutics Section, Medicine Branch, National Cancer Institute, Bethesda, MD 20892, USA
Novartis Found Symp 243:83-96; discussion 96-102, 180-5. 2002..Using third generation Pgp antagonists and properly designed clinical trials, it should be possible to determine the contribution of modulators to the reversal of clinical drug resistance... - Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasmsA M Senderowicz
Developmental Therapeutics Program Clinical Trials Unit, Medicine Branch, Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 16:2986-99. 1998.... - Suramin administration is associated with a decrease in serum calcium levelsM M Walther
Urologic Oncology Branch, DCS NCI NIH, Bethesda, MD 20892 1501, USA
World J Urol 18:388-91. 2000..Suramin placed in calcium controls did not affect calcium determination using three commercially available methods... - Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasmsE A Sausville
Developmental Therapeutics Program Clinical Trials Unit, Medicine Branch, and Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20852, USA
J Clin Oncol 19:2319-33. 2001..To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-hour continuous intravenous infusion (CIV)... - Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833I Chico
Medicine Branch and Department of Pathology, Division of Clinical Sciences, National Cancer Institute, National Institutesof Health, Bethesda, MD 20892, USA
J Clin Oncol 19:832-42. 2001..Future development of combinations such as this should include strategies to predict pharmacokinetics of the chemotherapeutic agent. This in turn will facilitate dosing to achieve comparable CPss and AUCs... - A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancerW D Figg
Medicine Branch, Division of Clinical Services, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Semin Oncol 28:62-6. 2001..Combining a cytotoxic agent with an angiogenesis inhibitor is a promising area of investigation for prostate cancer management... - Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitorJ Horti
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
Br J Cancer 79:1588-93. 1999..Increased AR transcription was also reflected at the protein level. In conclusion, TNP-470 and AGM-1883 both up-regulated PSA making clinical utilization of this surrogate marker problematic... - Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanismsH R Alexander
Surgical Metabolism Section, Surgery Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 4:2357-62. 1998..These data indicate that TNF must continue to be critically evaluated in clinical trials before it is routinely used with melphalan in isolated organ perfusion... - Thalidomide neuropathy in patients treated for metastatic prostate cancerF M Molloy
EMG Section, National Institute of Neurological Disorders and Stroke (NINDS, 10 Center Drive, MSC 1404, Bethesda, Maryland 20892-1404, USA
Muscle Nerve 24:1050-7. 2001..Older age and cumulative dose were possible contributing factors. Neuropathy may thus be a common complication of thalidomide in older patients. The SNAP index can be used to monitor peripheral neuropathy, but not for early detection... - Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulationsE C Kohn
Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
J Clin Oncol 15:1985-93. 1997..An encapsulated micronized powder formulation has been developed to optimize CAI administration. A phase I dose escalation trial with pharmacokinetic analysis has been performed... - Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphomaQin C Ryan
Clinical Trials Unit, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
J Clin Oncol 23:3912-22. 2005..Histone deacetylase inhibition was observed in peripheral-blood mononuclear-cells. Based on PK data from the q14-day schedule, a more frequent dosing schedule, weekly x 4, repeated every 6 weeks is presently being evaluated... - Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activityNilofer S Azad
Medical Oncology Branch, Biostatistics and Data Management Section, and Genetics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA
J Clin Oncol 26:3709-14. 2008..Bevacizumab is a monoclonal antibody targeted against VEGF. We hypothesized that the complementary inhibition of VEGF signaling would have synergistic therapeutic effects... - National Cancer Institute intramural approach to advanced prostate cancerPhilip M Arlen
Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Clin Prostate Cancer 1:153-62. 2002.... - Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancerYang Min Ning
PharmD, Bldg 10 Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA
J Clin Oncol 28:2070-6. 2010..These results suggest that definitive clinical trials combining antiangiogenic agent combinations with docetaxel are warranted to improve treatment outcomes for patients with metastatic CRPC... - Effect of ABCG2 genotype on the oral bioavailability of topotecanAlex Sparreboom
Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland, USA
Cancer Biol Ther 4:650-8. 2005..0% versus 31.4%; p = 0.037). It is suggested that the high frequency of the A allele in certain ethnic groups may have therapeutic implications for individuals treated with topotecan or other ABCG2 substrates... - Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assayE A Kruger
Medicine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 7:1867-72. 2001..We conclude that assays such as the human serum rat aortic ring bioassay may prove useful in predicting the concentrations of protein-bound antiangiogenic agents required for free fraction biological activity... - A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphomaR A Messmann
Developmental Therapeutics Program, Clinical Trials Unit, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892 1906, USA
Clin Cancer Res 6:1302-13. 2000.... - Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancerD L Bartlett
Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Surgery 129:176-87. 2001..HAI appears to prolong the duration of response after IHP, and this combined treatment strategy deserves additional clinical evaluation as a therapeutic modality in this setting... - Reversible sideroblastic anemia associated with the tetracycline analogue COL-3M A Rudek
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Am J Hematol 67:51-3. 2001..Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases. Am. J. Hematol. 67:51-53, 2001. Published 2001 Wiley-Liss, Inc... - A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablationWilliam D Figg
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
J Urol 181:1104-13; discussion 1113. 2009..We determined whether thalidomide can prolong progression-free survival in men with biochemically recurrent prostate cancer treated with limited androgen deprivation therapy... - Angiogenesis inhibitors in the treatment of prostate cancerPaul G Kluetz
National Cancer Institute, Medical Oncology Branch, Building 10, Room 12N226, 9000 Rockville Pike Bethesda, MD 20892, USA
Expert Opin Pharmacother 11:233-47. 2010..S. men. The efficacy of docetaxel and prednisone in metastatic castrate-resistant prostate cancer (mCRPC) has been shown to improve overall survival; however, its effect is not durable, highlighting the need for new therapies... - A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancerA Thibault
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Tumori 84:87-9. 1998..CONCLUSIONS: We conclude that decitabine is a well tolerated regimen with modest clinical activity against hormone-independent prostate cancer. Further investigations in patients of African-American origin may be warranted... - The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxelM H Kang
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 7:1610-7. 2001..CONCLUSIONS: PSC 833 increases the plasma concentration of 6alpha-hydroxypaclitaxel during paclitaxel therapy. Inhibition of cytochrome P-450 3A4 by PSC 833 may explain this in part, although other mechanisms cannot be excluded... - Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancerR C Bergan
Department of Cell and Cancer Biology, National Cancer Institute, Bethesda, Maryland, USA
J Natl Med Assoc 89:622-8. 1997..These findings are consistent with the hypothesis that therapies that work through mechanisms independent of the androgen receptor may result in similar outcomes across ethnic groups... - Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancerAntoinette R Tan
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
Clin Cancer Res 10:5038-47. 2004..Dose escalation of a 1-hour infusion of flavopiridol with docetaxel was also not possible. The changes in p53 and phospho-Rb in buccal mucosa suggest that a biological effect with flavopiridol was achieved... - Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxelMichael C Cox
Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland 20889, USA
Clin Cancer Res 12:4636-40. 2006..CONCLUSIONS: This study indicates that garlic does not significantly affect the disposition of docetaxel. However, it cannot be excluded that garlic decreases the clearance of docetaxel in patients carrying a CYP3A5*1A allele... - Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignanciesJames F Pingpank
Surgical Metabolism Section, Surgery Branch, National Cancer Institute/National Institutes of Health, Bethesda, MD 20892-1502, USA
J Clin Oncol 23:3465-74. 2005..CONCLUSION: Delivery of melphalan via this system is feasible, with limited, manageable toxicity and evidence of substantial antitumor activity; 3 mg/kg is the maximum safe tolerated dose of melphalan administered via this technique... - A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancerNima Sharifi
Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA
BJU Int 102:617-21. 2008.... - A phase II study of perifosine in androgen independent prostate cancerEdwin M Posadas
Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
Cancer Biol Ther 4:1133-7. 2005..No significant clinical activity against prostate cancer was observed. This agent does not merit further study in the setting of monotherapy in this population... - Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancerMilin R Acharya
Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD, USA
Invest New Drugs 24:367-75. 2006..Furthermore, MS-275 can be added to the list of cancer drugs where BSA-based dosing is not more accurate than fixed dosing... - ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxelTristan M Sissung
Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 14:4543-9. 2008..Polymorphisms that are associated with ABCB1 expression and function may be linked to treatment efficacy and the development of neutropenia and neurotoxicity in patients with androgen-independent prostate cancer receiving docetaxel... - Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancerWilliam L Dahut
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Clin Oncol 22:2532-9. 2004..After the prophylactic low-molecular-weight heparin was instituted to prevent venous thromboses, the combination regimen was well tolerated. Larger randomized trials are warranted to assess the impact of this combination... - Suramin's development: what did we learn?Maninderjeet Kaur
Molecular Pharmacology Section, Cancer Therapeutic Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
Invest New Drugs 20:209-19. 2002..These lessons can be applied to all clinical trials in hormone refractory prostate cancer. Suramin has significantly enhanced the evolution of our knowledge in several areas of prostate cancer biology and treatment... - Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasmsSuoping Zhai
Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Anticancer Drugs 14:125-35. 2003..The pharmacogenetic analyses did not support that the UGT1A1 promoter polymorphism could affect flavopiridol pharmacokinetics and alter the incidence and severity of diarrhea induced by the drug... - Phenylacetate pharmacokinetics based on iterative two-stage population analysisA H Burstein
Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Maryland, USA
Pharmacotherapy 21:281-6. 2001..06, 1.66), and 0.0038 (0.0019, 0.0058) hour(-1), respectively. CONCLUSION: The results of this study are similar to previous pharmacokinetic evaluations using the Abbottbase PKS system but suggest that earlier analyses were suboptimal... - Drug-induced lupus associated with COL-3: report of 3 casesJ V Ghate
Dermatology Branch, National Institutes of Health, Bldg 10, Room 12N238, Bethesda, MD 20892-1908, USA
Arch Dermatol 137:471-4. 2001..The rapid onset and the phototoxic appearance of the accompanying eruptions might suggest that damage to the keratinocytes caused the formation of neoantigens to which autoantibodies formed... - The androgen receptor gene and its influence on the development and progression of prostate cancerJ S Montgomery
Cancer Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA
J Pathol 195:138-46. 2001..Further study of the function of the androgen receptor will offer a better understanding of prostate cancer pathogenesis and progression, aiding the development of more effective treatments for this disease... - Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical developmentSuoping Zhai
Center for Cancer Research, National Cancer Institute, Building 10 Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892, USA
Ann Pharmacother 36:905-11. 2002..To review preclinical and clinical information on flavopiridol, an inhibitor of cyclin-dependent kinases (CDKs), tested as an antitumor agent... - Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasmsAntoinette R Tan
Center for Cancer Research, Developmental Therapeutics Program, and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 20:4074-82. 2002..Further studies to determine the optimal schedule of flavopiridol as a single agent and in combination with chemotherapeutic agents are underway... - Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumorsCliona Grant
Medical Oncology Branch, SAIC Frederick, NCI Frederick, MA, USA
Expert Rev Anticancer Ther 10:997-1008. 2010.... - Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assayGordon R Macpherson
Molecular Pharmacology Laboratory, Laboratory of Receptor Biology and Gene Expression, and Cell and Cancer Biology Branch and Vascular Biology Faculty, National Cancer Institute, Bethesda, MD 20892, USA
Mol Cancer Ther 2:845-54. 2003..In view of this in vitro data, we suggest that clinical trials involving endostatin treatment of late-stage disease may not adequately represent the efficacy of this drug in early-stage cancer... - Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to boneShenhong L Wu
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
BJU Int 99:525-8. 2007.... - A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumorsNilofer Azad
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Cancer Biol Ther 8:1800-5. 2009..We hypothesized daily oral micronized CAI with q3 week paclitaxel would be well-tolerated and active... - Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancerJeanny B Aragon Ching
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bathesda, MD, USA
BJU Int 100:1245-8. 2007..To assess the significance of viable tumour in the prostate of patients with metastatic androgen-independent prostate cancer (AIPC)... - Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer modelHaiqing Li
Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
BJU Int 101:884-8. 2008.... - Pharmacogenetics of irinotecan metabolism and transport: an updateNicola F Smith
Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
Toxicol In Vitro 20:163-75. 2006..This report provides an update on current strategies to individualize irinotecan chemotherapy based on each patient's genetic constitution, which may ultimately lead to more selective use of this agent... - Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxelNicola F Smith
Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Biol Ther 4:815-8. 2005..These data suggest that OATP1B3 is a key regulator of hepatic uptake, and may therefore play a role in the variable response to treatment with taxanes... - The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancerAvi S Retter
Center for Cancer Research, National Cancer Institute/NIH, 10 Center Drive, 12N226, Bethesda, MD 20892, USA
Clin Prostate Cancer 2:153-9. 2003..This article will review the background of angiogenesis inhibition and the use of such combinations in metastatic prostate cancer... - Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient miceSylvia S W Ng
Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
Clin Cancer Res 10:4192-7. 2004..PDGF signaling pathway may be a potential target for these thalidomide analogs. Detailed microarray and functional analyses are under way with the aim of elucidating the molecular mechanism(s) of action of these thalidomide analogs... - Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomideYuichi Ando
Molecular Pharmacology Section, Cancer Therapeutic Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Biol Ther 1:669-73. 2002..Although this study had no power to detect the statistical significance of the CYP2C19 genotype, the findings were consistent with our hypothesis. The role of CYP2C19 polymorphism in thalidomide treatments remains to be elucidated... - Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancerJ B Sunwoo
Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD 20892, USA
J Clin Oncol 19:800-11. 2001..CONCLUSION: Paclitaxel administered as a 120-hour continuous infusion in combination with radiotherapy is a feasible and promising treatment for patients with advanced HNSCC... - Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanningJ A Carrasquillo
Nuclear Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1180, USA
J Nucl Med 42:1359-63. 2001..Use of alendronate before bone scanning is unlikely to result in decreased detection of lesions or falsely decreased 99mTc-MDP activity at metastatic bone tumor sites... - Reversal of docetaxel resistance with bevacizumab and thalidomideYang Min Ning
DDOP OODP CDER, Food and Drug Administration, Silver Spring, MD, USA
Clin Genitourin Cancer 7:E37-8. 2009..The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study... - ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancerHaiqing Li
Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Anticancer Drugs 18:563-8. 2007..We detected cytotoxic activity in human umbilical vein endothelial cells, PC3, and Tsu-Pr1 cells, when ADH1 exposure was evaluated at 500 micromol/l or above... - Mutations in the EGFR: the importance of genotypingDouglas K Price
Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Biol Ther 3:434-5. 2004..and Paez et al. help to explain those initial clinical findings. Both groups report that somatic mutations found within the coding region of the EGFR may predict the sensitivity to gefitinib treatment... - Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacyWilfred D Stein
Medical Oncology Branch and Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 17:907-17. 2011..We utilized a method estimating tumor growth and regression rate constants from serial PSA measurements, and assessed its potential in patients with metastatic castration resistant prostate carcinoma (mCRPC)... - Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignanciesShivaani Kummar
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 13:5411-7. 2007..The aims of this phase I trial were to determine the dose-limiting toxicities and maximum tolerated dose of oral MS-275 in humans administered with food on a once weekly schedule and to study the pharmacokinetics of oral MS-275... - Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patientsErin R Lepper
Science Applications International Corporation Frederick, Maryland, USA
Clin Cancer Res 11:7398-404. 2005..To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in patients with cancer receiving midazolam as a phenotyping probe... - Androgen receptor modulation: lessons learned from beyond the prostateNima Sharifi
Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Biol Ther 6:1358-9. 2007..Here, we examine recent findings from the description of a compound that degrades AR and induces dissociation of AR from an AR coactivator. The biochemistry of this compound may have implications for prostate cancer... - Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug eliminationNicola F Smith
National Cancer Institute, Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, 9000 Rockville Pike, Bethesda, MD 20892, USA
Expert Opin Drug Metab Toxicol 1:429-45. 2005..Alteration of transporter function by either of these mechanisms may contribute to interindividual variability in drug disposition and response. In this review an update of this rapidly emerging field is provided... - A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumorsHoward A Fine
Neuro Oncology Branch and Medical Oncology Branch, National Cancer Institute, The National Institute of Neurological Disorders and Stroke, Bethesda, Maryland 20892, USA
Clin Cancer Res 13:7101-6. 2007.... - Pharmacogenetics of membrane transporters: a review of current approachesTristan M Sissung
Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
Methods Mol Biol 448:41-62. 2008..Finally, studies linking transporter genotype with clinical outcomes are discussed... - Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapySylvia S W Ng
Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Cancer Biol Ther 3:1212-3. 2004..Thrombospondin-1, in turn, promotes endothelial cell apoptosis. It was also proposed that thrombospondin-1 levels might be used as a surrogate marker to monitor response to low-dose cyclophosphamide therapy in the clinic... - Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometryKyunghwa Hwang
Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA
J Chromatogr B Analyt Technol Biomed Life Sci 804:289-94. 2004..The values for precision and accuracy were always < or =5.58 and <11.4% relative error, respectively. The method was successfully applied to examine the pharmacokinetics of MS-275 in a cancer patient... - Molecular alterations in primary prostate cancer after androgen ablation therapyCarolyn J M Best
Pathogenetics Unit, Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 11:6823-34. 2005..The molecular mechanisms underlying progression are not well known in part due to the rarity of androgen-independent samples from primary and metastatic sites... - Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteinsSylvia S W Ng
Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, and Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Cancer Res 64:821-4. 2004..It is suggested that these agents may need to be used at much higher doses than anticipated for effective antiangiogenic chemotherapy... - Pharmacogenetics of membrane transporters: an update on current approachesTristan M Sissung
Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Mol Biotechnol 44:152-67. 2010..A comprehensive list of substrates for the major drug transporters is included. Finally, studies linking transporter genotype with clinical outcomes are discussed... - A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomasShivaani Kummar
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Chemother Pharmacol 65:383-9. 2010..We designed a phase I study to determine the maximum tolerated dose (MTD) of UCN-01 with prednisone in patients with advanced malignancies... - A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapyJames L Gulley
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Urol 173:1567-71. 2005..We present the largest published series of patients evaluating the timing of T and DHT increase after cessation of GnRH therapy... - Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropeniaTristan M Sissung
Clinical Pharmacology Research Core, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA
Eur J Cancer 42:2893-6. 2006..This pilot study suggests that paclitaxel-induced neuropathy and neutropenia might be linked to inherited variants of ABCB1 through a mechanism that is unrelated to altered plasma pharmacokinetics... - Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphomaSusan E Bates
Medical Oncology Branch, National Institutes of Health, Bethesda, MD 20892, USA
Br J Haematol 148:256-67. 2010.... - Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancerMcDonald K Horne
Department of Laboratory Medicine, Hematology Service, W.G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
Pharmacotherapy 23:315-8. 2003..Clinicians should be aware of this potential complication when adding thalidomide to chemotherapeutic regimens... - Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleuraDavid S Schrump
Thoracic Oncology Section Surgery Branch, Cancer Therapy Evaluation Program, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
Clin Cancer Res 12:5777-85. 2006..A phase I trial was done to examine pharmacokinetics, toxicities, and gene expression mediated by 5-aza-2'-deoxycytidine (DAC) in patients with thoracic malignancies... - Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancerJames L Gulley
Center for Cancer Research, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
J Urol 180:1432-7; discussion 1437. 2008..To our knowledge this represents the largest study using monthly testosterone and dihydroxytestosterone measurement to evaluate the kinetics of androgen recovery following limited androgen deprivation therapy... - Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteersRyszard M Pluta
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS ONE 6:e14504. 2011..The study was developed to determine the safety and feasibility of prolonged sodium nitrite infusion... - Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analoguesSylvia S W Ng
Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Cancer Res 63:3189-94. 2003..The in vivo toxicity of representative analogues from each class was also evaluated. Taken together, our results support the further development and evaluation of novel thalidomide analogues as antiangiogenic agents... - Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerationsS C Piscitelli
Department of Pharmacy, National Institutes of Health, Bethesda, Maryland, USA
Clin Pharmacokinet 32:368-81. 1997..An increased understanding of the many factors which can alter the analysis and pharmacokinetics of cytokines is essential to the design of optimal dosage regimens... - The control of prostate-specific antigen expression and gene regulation by pharmacological agentsS C Dixon
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Pharmacol Rev 53:73-91. 2001..The implications of these findings in the evaluation of new agents in androgen-independent prostate cancer will be considered...